CSBR

Business Context and Reporting Period

Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended January 31, 2026
Business Overview: The Company is a technology-enabled research organization providing oncology drug discovery and development services. Its core offering is the TumorGraft Technology Platform, which utilizes Patient Derived Xenograft (PDX) models to predict drug efficacy. The Company operates in a single reportable segment.

Key Financial Metrics

Note: Working capital is calculated as Total Current Assets ($20,185) minus Total Current Liabilities ($20,677).

Material Changes vs. Prior Period

• Revenue: For the nine months ended January 31, 2026, revenue increased 2.2% to $45.6 million compared to $44.6 million in the prior year. However, the three-month period saw a 2.8% decline to $16.6 million.
• Profitability: The Company reported a net loss of $0.5 million for the nine months ended January 31, 2026, a significant reversal from the $6.5 million net income reported in the same period in 2025. Operating loss for the nine months was $0.6 million versus operating income of $6.6 million in the prior year.
• Cost Structure: Cost of oncology revenue increased 14.1% year-over-year for the nine-month period, driven primarily by over $2.0 million in outsourced radiolabeling work. Research and development expenses rose 43.3% due to increased outsourcing for sequencing and higher compensation.
• Cash Flow: Net cash used in operating activities was $2.5 million for the nine months ended January 31, 2026, compared to $0.5 million provided by operations in the prior year. This shift was largely due to a decrease in deferred revenue reflecting lower upfront billings.
• Deferred Revenue: Deferred revenue decreased significantly from $15.4 million at April 30, 2025, to $10.0 million at January 31, 2026.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes cash on hand ($7.1 million) and expected cash flows are adequate to fund operations through at least March 2027, despite negative working capital and operating cash burn.
• Strategic Shifts: The Company is transitioning radiolabeling work from third-party vendors to internal laboratories to improve cost structure. There is a strategic de-emphasis on flow cytometry services, contributing to lower "Other TOS" revenue.
• Investment in Growth: Sales and marketing expenses increased 24.5% year-over-year to support commercial expansion for core research services and data licensing initiatives.
• Risks: As a smaller reporting company, the filing does not detail specific risk factors but references the 2025 Annual Report. General risks include economic uncertainty, supply chain disruptions, and the inability to raise additional capital if required.
• Unusual Items: The Company recorded a loss of $110,000 on the disposal of lab equipment during the nine-month period. Additionally, a gain of $9,000 was recorded on the early termination of an operating lease in Italy.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the $7.1 million cash balance given the $2.5 million operating cash burn over nine months and negative working capital.
• Revenue Quality: Assess the impact of the $4.5 million TOS data license revenue recognized in the prior year (absent in the current quarter) on future revenue stability.
• Cost Transition: Monitor the timeline and cost savings associated with moving radiolabeling operations in-house.
• Deferred Revenue: Investigate the reasons behind the $5.4 million decrease in deferred revenue and its implication for future booking momentum.
• Stock-Based Compensation: Note the $0.9 million in stock-based compensation expense for the nine months and the $4.1 million remaining unrecognized expense, which impacts future dilution and expenses.